FDA Approves Immunotherapy That May Allow Certain Patients With Rectal Cancer To Avoid Chemotherapy, Radiation And Surgery

The FDA has approved a new immunotherapy treatment that may enable specific patients with rectal cancer to bypass traditional chemotherapy, radiation, and surgery. This approval could significantly impact treatment protocols for rectal cancer, potentially improving patient outcomes. The stock ticker for the company involved in this development is GSK.